How logically impossible patents block biosimilars

Deep patent portfolios help drugmakers block market entry by potential biosimilars, but many biologic patents logically cannot be valid barriers to competitive entry. Access through your

institution Buy or subscribe This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. * THE DIVISIONAL GAME: USING

PROCEDURAL RIGHTS TO IMPEDE GENERIC/BIOSIMILAR MARKET ENTRY * Katarina Foss-Solbrekk _IIC - International Review of Intellectual Property and Competition Law_ Open Access 04 August 2022

ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time

Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access

to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our

FAQs * Contact customer support REFERENCES * Chen, B. K., Yang, Y. T. & Bennett, C. L. _Drugs_ 78, 1777–1781 (2018). Article  Google Scholar  * Biologic Patent Transparency Act, S.659

https://www.congress.gov/bill/116th-congress/senate-bill/659/text (2019). * Brennan, Z. Six lawsuits target AbbVie’s Humira and its patent thicket. _Regulatory Focus_

https://www.raps.org/news-and-articles/news-articles/2019/4/six-lawsuits-target-abbvies-humira-and-its-patent (2 April 2019). * _Metallizing Engineering Co. v. Kenyon Bearing & Auto

Parts Co_., 153 F.2d 516 (2d Cir. 1946). * 21 USC § 372(d). * 42 USC § 262(l). * Price, W. N. II & Rai, A. K. _Science_ 348, 188–189 (2015). Article  CAS  Google Scholar  * Kapczynski,

A. 59 UCLA L. Rev. 970 (2012). * Genentech files complaint against Pfizer regarding Herceptin. _Big Molecule Watch_

https://www.bigmoleculewatch.com/2017/11/21/genentech-files-complaint-against-pfizer-regarding-herceptin/ (21 November 2017). * Overpatented, overpriced: special Humira edition. _I-MAK_

http://www.i-mak.org/wp-content/uploads/2018/09/i-mak.humira.report.final_.0917.pdf (17 September 2018). Download references ACKNOWLEDGEMENTS The authors thank B. Potter and B. Wright for

research assistance. WNP’s work was supported by the Cook Fund at the University of Michigan Law School and the Novo Nordisk Foundation (NNF17SA0027784). AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * University of Michigan Law School, Ann Arbor, MI, USA W. Nicholson Price II * Centre for Advanced Studies in Biomedical Innovation Law, Copenhagen, Denmark W. Nicholson Price

II * Duke University Law School and Duke-Margolis Center for Health Policy, Durham, NC, USA Arti K. Rai Authors * W. Nicholson Price II View author publications You can also search for this

author inPubMed Google Scholar * Arti K. Rai View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to W. Nicholson Price

II. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Price, W.N., Rai,

A.K. How logically impossible patents block biosimilars. _Nat Biotechnol_ 37, 862–863 (2019). https://doi.org/10.1038/s41587-019-0196-x Download citation * Published: 02 August 2019 * Issue

Date: August 2019 * DOI: https://doi.org/10.1038/s41587-019-0196-x SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative